Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-16
H
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Henrique Rodrigues' research focuses on understanding the molecular mechanisms that contribute to cancer radioresistance, particularly in pancreatic and thyroid malignancies. His work has identified signaling pathways, such as the RAS-RAF-miR-296-3p axis, that can increase the expression of Rad18, thereby augmenting resistance to radiation therapy. Rodrigues has also investigated the role of SETD2 in rectal cancer, finding that its loss predicts response to chemoradiotherapy and validating these findings in preclinical models. Further research includes exploring methods to enhance rectal cancer radiosensitivity and protect the gut through dietary interventions like methionine restriction.
Rodrigues is affiliated with the University of Arkansas for Medical Sciences and collaborates with researchers including Oscar Zuniga and Lokesh Akana. His published work spans 2024-2025, with a recent focus on cancer biology and treatment. His scholarship metrics include an h-index of 5, with 26 total publications and 254 total citations.
Metrics
- h-index: 5
- Publications: 26
- Citations: 254
Selected Publications
-
Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer (2025)
-
SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models (2025)
-
Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction (2025)
-
Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1 (2024)
-
RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers (2024)
-
Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer (2024)
-
Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy (2023)
-
Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer (2023)
Collaboration Network
Top Collaborators
Adam R. Wolfe
University of Arkansas for Medical Sciences
8 shared publications
In database
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Showing 5 of 8 shared publications
Lokesh Akana
University of Arkansas for Medical Sciences
6 shared publications
In database
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- SETD2 Loss Predicts Response to Chemoradiotherapy in Rectal Cancer: Clinical Outcomes and Preclinical Validation in Orthotopic Models
Showing 5 of 6 shared publications
Oscar Zuniga
University of Arkansas for Medical Sciences
4 shared publications
In database
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A006: Targeting SETD2 in combination with radiotherapy in rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Saaimatul Huq
University of Arkansas for Medical Sciences
3 shared publications
In database
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
- Abstract A033: Targeting SETD2 in Combination with Radiotherapy in Rectal Cancer
Sarita Garg
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Stetson Van Matre
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Abstract A011: Enhanced Radiosensitivity of Pancreatic Cancer Achieved through Inhibition of Cyclin-Dependent Kinase 1
Nükhet Aykin‐Burns
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Isabelle R. Miousse
University of Arkansas for Medical Sciences
2 shared publications
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
- Enhancing Rectal Cancer Radiosensitivity and Gut Protection through Methionine Restriction
Robin Eluvathingal
University of Arkansas for Medical Sciences
1 shared publication
In database
- Abstract 2839: Methionine restriction radiosensitizes KRAS mutant rectal cancer
A.Z. Kesaria
University of Arkansas for Medical Sciences (US)
1 shared publication
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
Eric U. Yee
University of Arkansas for Medical Sciences
1 shared publication
In database
- Targeting Tri-Methyl-Histone H3 (Lys27) in Rectal Cancer: A Novel Strategy to Enhance Radiosensitivity and Predict Response to Neoadjuvant Therapy
Haihua Feng
City of Hope (US)
1 shared publication
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
Daniel E. Eldridge
Winthrop Rockefeller Foundation (US)
1 shared publication
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
Linlin Yang
City of Hope (US)
1 shared publication
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
Changxian Shen
City of Hope (US)
1 shared publication
- RAS-RAF-miR-296-3p signaling axis increases Rad18 expression to augment radioresistance in pancreatic and thyroid cancers
Similar Researchers
Based on overlapping research topics
Oscar Zuniga
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Gene expression and cancer classification
Fenghuang Zhan
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Gene expression and cancer classification
Meta-analysis and systematic reviews
Natarajan Ganesan
Arkansas State University
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Robin Eluvathingal
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Radiation Therapy and Dosimetry
Cancer Treatment and Pharmacology
Lauren C. Morehead
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Cancer Treatment and Pharmacology
Meta-analysis and systematic reviews
Parmis Hassanbeigi
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Meta-analysis and systematic reviews
Diet and metabolism studies